person · Reporting owner
HUEMOELLER JOHN WALTER II
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Director · Chief Executive Officer | March 15, 2024 | March 19, 2024 |
| PLEDGE PETROLEUM CORPPROP · Entity 161031 | Director | May 02, 2018 | May 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date March 15, 2024 · Filed March 19, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2033-01-24 | Direct | 30,000,000 |
Reported balance
After 2024-03-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-03-15 · Grant · Acquired 250,000 · Balance 30,000,000 F1: Reporting Person acquired an Amended Convertible Promissory Note in the face amount of $250,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2034-03-01 | Direct | 42,500,000 |
Reported balance
After 2024-03-15 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2024-03-15 · Grant · Acquired 250,000 · Balance 42,500,000 F2: Reporting Person acquired a convertible note, face value $250,000. The note is convertible into shares of Issuer's common stock at a price of $0.02 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person acquired an Amended Convertible Promissory Note in the face amount of $250,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.
F2: Reporting Person acquired a convertible note, face value $250,000. The note is convertible into shares of Issuer's common stock at a price of $0.02 per share.
PLEDGE PETROLEUM CORP
Report date May 02, 2018 · Filed May 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000,000 |
Reported balance
After 2018-05-03 transaction · row 1
1 source rowRow 1 · 2018-05-03 · Other · Acquired 10,000,000 · Balance 20,000,000 F1: On May 2, 2018, the Issuer granted shares of restricted stock to Mr. Huemoeller vesting as to 1/3rd upon the grant date, 1/3rd on the one year anniversary of the grant date and 1/3rd on the two year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 2, 2018, the Issuer granted shares of restricted stock to Mr. Huemoeller vesting as to 1/3rd upon the grant date, 1/3rd on the one year anniversary of the grant date and 1/3rd on the two year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 19:59 UTC Amendment | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 250,000 | $250,000.00 Strike: $0.02 | $62,500,000,000.00 |
DisclosureSEC source: 0001096906-24-000525 · form4.xml · derivative · entry 2 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500,000 Underlying: Common Stock · 12,500,000 shares Expires 2034-03-01 F2 · shares: Reporting Person acquired a convertible note, face value $250,000. The note is convertible into shares of Issuer's common stock at a price of $0.02 per share. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 19:59 UTC Amendment | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 250,000 | $250,000.00 Strike: $0.01 | $62,500,000,000.00 |
DisclosureSEC source: 0001096906-24-000525 · form4.xml · derivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000,000 Underlying: Common Stock · 25,000,000 shares Expires 2033-01-24 F1 · shares: Reporting Person acquired an Amended Convertible Promissory Note in the face amount of $250,000. The Note is convertible into shares of the Issuer's common stock at a price of $0.01 per share. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 19:14 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 1 | $250,000.00 Strike: $0.02 | $250,000.00 |
DisclosureSEC source: 0001096906-24-000509 · form4.xml · derivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500,000 Underlying: Common Stock · 12,500,000 shares Expires 2034-03-01 F1 · shares: Reporting Person acquired a convertible note, face value $250,000. The note is convertible into shares of Issuer's common stock at a price of $0.02 per share. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 16:20 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 5,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001096906-22-002331 · form4.xml · derivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000,000 Underlying: Common Stock · 5,000,000 shares Expires 2032-08-22 F1 · derivative.exercise_date: Reporting Person acquired an option to purchase up to 5,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may purchased at the date which is six (6) months following the grant date. Read SEC document |
| May 06, 2021 Filed Sep 23, 2022 16:17 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | Disposition to issuerOption · Derivative | 2,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001096906-22-002330 · form4.xml · derivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2039-01-01 F1 · kind: On May 6, 2021, Reporting Person voluntarily agreed to cancel the option to purchase 2,000,000 shares of the Issuer's common stock granted to Reporting Person on January 2, 2019. Read SEC document |
| December 10, 2020 Filed Sep 23, 2022 16:16 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 3,000,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001096906-22-002329 · form4.xml · derivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2030-12-10 Read SEC document |
| March 19, 2020 Filed Sep 23, 2022 16:14 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | PurchaseCommon Stock | 6,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001096906-22-002328 · form4.xml · nonDerivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000,000 F1 · price: Reporting Person acquired the shares pursuant to a share exchange with the Issuer whereby Reporting Person exchanged 100% of the Sapphire Biotech, Inc. shares common stock held by Reporting Person for 6,000,000 shares of common stock of the Issuer. Read SEC document |
| January 02, 2019 Filed Sep 23, 2022 16:11 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantOption · Derivative | 2,000,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001096906-22-002327 · form4.xml · derivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2039-01-01 F1 · derivative.exercise_date: On January 2, 2019, Reporting Person acquired an option to purchase up to 2,000,000 shares of common stock. 50% of the shares may be purchased immediately and the remaining 50% of the shares may be purchased at the date which is six (6) months following the grant date. Read SEC document |
| May 03, 2018 Filed May 3, 2018 16:37 UTC | PLEDGE PETROLEUM CORP PROP · Entity 161031 | OtherCommon Stock | 10,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-025112 · tv492976_4.xml · nonDerivative · entry 1 HUEMOELLER JOHN WALTER II · CIK 0001568485 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000,000 F1 · kind: On May 2, 2018, the Issuer granted shares of restricted stock to Mr. Huemoeller vesting as to 1/3rd upon the grant date, 1/3rd on the one year anniversary of the grant date and 1/3rd on the two year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.